Business
Admission to Trading on AIM and First Day of De...
Admission to Trading on AIM and First Day of De....
About this update from 4basebio Plc
[{"type":"text","content":"\n \n 4basebio UK Societas\n (\"4basebio\", the \"Company\" or the “Group”)\n Admission to Trading on AIM and First Day of Dealings\n 4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines, is pleased to announce the admission of its ordinary shares to trading on the AIM market of the London Stock Exchange. Dealings will commence at 8.00 a.m. today, Wednesday 17 February 2021, under the ticker 4BB (ISIN GB00BLD8ZL39).\n Upon Admission, the Company will have 12,317,473 ordinary shares in issue and a market capitalisation of approximately £14.5 million.\n Heikki Lanckriet, Chief Executive Officer of 4basebio, commented:\n “We are delighted to be admitted to AIM today. As a Cambridge based company with significant ambitions, we believe AIM is the ideal market to support our further development. We would also like to extend our thanks to our staff, advisors and shareholders who continue to support our ongoing growth strategy.”\n Cairn Financial Advisers LLP is acting as Nominated Adviser to the Company and finnCap is acting as Broker.\n Company Highlights\n 4basebio is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The immediate objectives of 4bb are to validate and scale its DNA synthesis and advance its collaborations to facilitate the functional validation of its DNA based products and gene delivery solutions.\n The Company divested from 4basebio AG (“4bb AG”), a German company listed on the Prime Standard segment of the Frankfurt Stock Exchange, following the disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology business to AIM-quoted Abcam plc in January 2020 for €120million. Following the disposal, 4bb AG retained its genomics business which owned and licensed certain intellectual property including its proprietary, patent-protected technology, TruePrime™. This is the foundation for building the Company’s synthetic DNA manufacturing business which 4bb AG transferred to the Co...